Keytruda (pembrolizumab) is now approved as perioperative treatment for patients with head and neck squamous cell carcinoma.

The FDA has approved Zusduri (mitomycin intravesical solution) to treat adults with recurrent, low-grade, intermediate-risk NMIBC.

The US Food and Drug Administration (FDA) has approved a new tablet formulation of Brukinsa (zanubrutinib), which is expected to replace the current capsule formulation in October 2025. Brukinsa, a ...